Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatment

被引：0
|
作者：
Ylisaukko-Oja, T. [1 ]
Af Bjorkesten, C. G. [2 ,3 ]
Erbel, A. [2 ,3 ]
Nuutinen, H. [4 ]
Jussila, A. [5 ]
Molander, P. [2 ,3 ]
Koskela, R. [6 ]
Blomster, T. [6 ]
Pajala, M. [7 ]
Ilus, T. [5 ]
Haiko, P. [8 ]
Kovac, B. [8 ]
Silvola, S. [8 ]
Smith, S. [1 ]
Jokelainen, J. [1 ]
Sipponen, T. [2 ,3 ]
机构：
[1] MedEngine Oy, Med Data Sci, Helsinki, Finland
[2] Univ Helsinki, Abdominal Ctr Gastroenterol, Helsinki, Finland
[3] Helsinki Univ Hosp, Abdominal Ctr Gastroenterol, Helsinki, Finland
[4] Turku Univ Hosp, Div Gastroenterol, Dept Med, Turku, Finland
[5] Tampere Univ Hosp, Dept Gastroenterol & Alimentary Tract Surg, Tampere, Finland
[6] Oulu Univ Hosp, Dept Med, Div Gastroenterol, Oulu, Finland
[7] Kuopio Univ Hosp, Dept Internal Med, Kuopio, Finland
[8] Takeda Oy, Helsinki, Finland
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P629
引用
收藏
页码：758 / 759
页数：2
相关论文
共 50 条
  • [1] Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment
    Ylisaukko-Oja, Tero
    af Bjorkesten, Clas-Goran
    Eberl, Anja
    Nuutinen, Heikki
    Jussila, Airi
    Molander, Pauliina
    Koskela, Ritva
    Blomster, Timo
    Pajala, Markku
    Ilus, Tuire
    Haiko, Paula
    Kovac, Bianca
    Silvola, Saija
    Smith, Sarah
    Jokelainen, Jari
    Sipponen, Taina
    HELIYON, 2024, 10 (12)
  • [2] Evaluation of treatment persistence of vedolizumab among Finnish inflammatory bowel disease patients in real-life clinical practice (FINVEDO)
    Ylisaukko-oja, T.
    Eberl, A.
    Aaltonen, J.
    Nuutinen, H.
    Blomster, T.
    Jussila, A.
    Pajala, M.
    Jokelainen, J.
    Herrala, S.
    Tamminen, K.
    Sipponen, T.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S342 - S342
  • [3] EVALUATION OF TREATMENT PERSISTENCE OF VEDOLIZUMAB AMONG FINNISH INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS IN REAL-LIFE CLINICAL PRACTICE (FINVEDO)
    Ylisaukko-Oja, Tero
    Eberl, Anja
    Aaltonen, Jaakko
    Nuutinen, Heikki
    Blomster, Timo
    Jussila, Airi
    Pajala, Markku
    Jokelainen, Jari
    Herrala, Sauli
    Tamminen, Klaus
    SIpponen, Taina
    GASTROENTEROLOGY, 2017, 152 (05) : S398 - S398
  • [4] Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice
    Shin, Jung Hyun
    Choo, Myung-Soo
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2019, 11 (03) : 151 - 157
  • [5] High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
    Ylisaukko-oja, Tero
    Aaltonen, Jaakko
    Nuutinen, Heikki
    Blomster, Timo
    Jussila, Airi
    Pajala, Markku
    Salminen, Kimmo
    Moilanen, Veikko
    Hakala, Kalle
    Kellokumpu, Mikko
    Toljamo, Kari
    Rautiainen, Henna
    Kuisma, Juha
    Peraaho, Markku
    Molander, Pauliina
    Silvennoinen, Jouni
    Liukkonen, Ville
    Henricson, Hans
    Tillonen, Jyrki
    Esterinen, Mirva
    Nielsen, Christian
    Hirsi, Eija
    Laane, Margus
    Suhonen, Ulla-Maija
    Vihriala, Ilkka
    Makela, Petri
    Puhto, Mika
    Punkkinen, Jari
    Sulonen, Hannu
    Herrala, Sauli
    Jokelainen, Jari
    Tamminen, Klaus
    Sipponen, Taina
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (02) : 158 - 167
  • [6] ITALIAN REAL-LIFE STUDY EVALUATING THE LONG TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Pugliese, Daniela
    Privitera, Giuseppe
    Crispino, Federica
    Mezzina, Nicolo
    Pellegrini, Lucienne
    Laterza, Lucrezia
    Viola, Anna
    Soru, Pietro
    Scrivo, Barbara
    Barberio, Brigida
    Ricci, Chiara
    Pluchino, Dario
    Scribano, Maria Lia
    Bertani, Lorenzo
    Sablich, Renato
    Pastorelli, Luca
    Manguso, Francesco
    Variola, Angela
    Di Sario, Antonio
    Grossi, Laurino
    Ribaldone, Davide Giuseppe
    Biscaglia, Giuseppe
    Buda, Andrea
    Balestrieri, Paola
    Mocci, Giammarco
    Viscido, Angelo
    Di Paolo, Maria Carla
    Onali, Sara
    Rodino, Stefano
    Coletta, Marina
    Principi, Mariabeatrice
    Miranda, Agnese
    Amato, Arnaldo
    Bezzio, Cristina
    Petruzzellis, Carlo
    Mazzuoli, Silvia
    Festa, Stefano
    Sartini, Alessandro
    Fanigliulo, Libera
    Gallina, Sara
    Bodini, Giorgia
    Guidi, Luisa
    Savarino, Edoardo
    Cappello, Maria
    Caprioli, Flavio
    Fries, Walter
    Scaldaferri, Franco
    Castiglione, Fabiana
    Massari, Alessandro
    Orlando, Ambrogio
    GASTROENTEROLOGY, 2020, 158 (06) : S955 - S955
  • [7] ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Pugliese, D.
    Privitera, G.
    Armuzzi, A.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S113 - S114
  • [8] ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Pugliese, Daniela
    Privitera, Giuseppe
    Armuzzi, Alessandro
    GASTROENTEROLOGY, 2023, 164 (06) : S1119 - S1120
  • [9] VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Haddley, K.
    DRUGS OF TODAY, 2014, 50 (04) : 309 - 319
  • [10] Effectiveness and persistence of vedolizumab in patients with Inflammatory bowel Disease: Results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)
    Reenaers, C.
    Cremer, A.
    Dewit, O.
    de Vroey, B.
    Van Moerkercke, W.
    Bossuyt, P.
    Muls, V.
    Imschoot, J.
    Block, S.
    Hantson, A.
    Van Hootegem, P.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S476 - S477
12345